{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:55:46Z","timestamp":1791320146203,"version":"4.3.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.14283\/jpad.2022.93","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T16:24:02Z","timestamp":1666196642000},"page":"19-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["ACU193, a Monoclonal Antibody that Selectively Binds Soluble A\u03b2 Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan"],"prefix":"10.1016","volume":"10","author":[{"given":"Eric","family":"Siemers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hitchcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sundell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Jerecic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Cline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Iverson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Edgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Manber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Fuin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Poppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.14283\/jpad.2022.93_bib1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.14283\/jpad.2021.54","article-title":"The Ups and Downs of Amyloid in Alzheimer's","volume":"9","author":"Siemers","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2022.93_bib2","doi-asserted-by":"crossref","DOI":"10.14283\/jpad.2022.30","article-title":"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease","author":"Budd Haeberlein","year":"2022","journal-title":"The Journal of Prevention of Alzheimer's Disease"},{"key":"10.14283\/jpad.2022.93_bib3","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in Early Alzheimer's Disease","author":"Mintun","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.14283\/jpad.2022.93_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401\u2014a clinical study in Alzheimer's disease with a protofibril selective A\u03b2 antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.14283\/jpad.2022.93_bib5","volume":"13","year":"2021","journal-title":"Alzheimer's Research & Therapy"},{"key":"10.14283\/jpad.2022.93_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.848215","article-title":"ACU193: An Immunotherapeutic Poised to Test the Amyloid \u03b2 Oligomer Hypothesis of Alzheimer's Disease","volume":"16","author":"Krafft","year":"2022","journal-title":"Frontiers in Neuroscience"},{"issue":"4","key":"10.14283\/jpad.2022.93_bib7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/alzrt272","article-title":"Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics","volume":"6","author":"Goure","year":"2014","journal-title":"Alzheimer's Research & Therapy"},{"issue":"8","key":"10.14283\/jpad.2022.93_bib8","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1523\/JNEUROSCI.1675-13.2014","article-title":"A Sensitive A\u03b2 Oligomer Assay Discriminates Alzheimer's and Aged Control Cerebrospinal Fluid","volume":"34","author":"Savage","year":"2014","journal-title":"Journal of Neuroscience"},{"issue":"44","key":"10.14283\/jpad.2022.93_bib9","doi-asserted-by":"crossref","first-page":"12749","DOI":"10.1021\/bi030029q","article-title":"Self-assembly of Abeta(1\u201342) into globular neurotoxins","volume":"42","author":"Chromy","year":"2003","journal-title":"Biochemistry"},{"issue":"11","key":"10.14283\/jpad.2022.93_bib10","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","article-title":"Diffusible, nonfibrillar ligands derived from A\u03b21-42 are potent central nervous system neurotoxins","volume":"95","author":"Lambert","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"10.14283\/jpad.2022.93_bib11","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1523\/JNEUROSCI.5161-07.2008","article-title":"Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization","volume":"28","author":"Klyubin","year":"2008","journal-title":"J Neurosci"},{"issue":"8","key":"10.14283\/jpad.2022.93_bib12","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm1782","article-title":"Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory","volume":"14","author":"Shankar","year":"2008","journal-title":"Nat Med"},{"key":"10.14283\/jpad.2022.93_bib13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1113\/jphysiol.2005.103754","article-title":"Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers","volume":"572","author":"Townsend","year":"2006","journal-title":"J Physiol"},{"key":"10.14283\/jpad.2022.93_bib14","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1042\/BST0331087","article-title":"The role of cell-derived oligomers of A\u03b2 in Alzheimer's disease and avenues for therapeutic intervention","volume":"33","author":"Walsh","year":"2005","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"10.14283\/jpad.2022.93_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nn1372","article-title":"Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function","volume":"8","author":"Cleary","year":"2005","journal-title":"Nat Neurosci"},{"issue":"2","key":"10.14283\/jpad.2022.93_bib16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bbr.2008.06.001","article-title":"Oligomers of the amyloid-beta protein disrupt working memory: confirmation with two behavioral procedures","volume":"193","author":"Poling","year":"2008","journal-title":"Behav Brain Res"},{"issue":"10","key":"10.14283\/jpad.2022.93_bib17","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.neurobiolaging.2009.11.007","article-title":"Cognitive effects of cell-derived and synthetically derived A\u03b2 oligomers","volume":"32","author":"Reed","year":"2011","journal-title":"Neurobiol Aging"},{"issue":"6","key":"10.14283\/jpad.2022.93_bib18","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ana.21051","article-title":"Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers","volume":"60","author":"Townsend","year":"2006","journal-title":"Ann Neurol"},{"issue":"3","key":"10.14283\/jpad.2022.93_bib19","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1471-4159.2005.03407.x","article-title":"Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease","volume":"95","author":"Barghorn","year":"2005","journal-title":"J Neurochem"},{"issue":"6","key":"10.14283\/jpad.2022.93_bib20","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.neuropharm.2011.01.051","article-title":"Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of beta-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices","volume":"60","author":"Rammes","year":"2011","journal-title":"Neuropharmacology"},{"issue":"S1","key":"10.14283\/jpad.2022.93_bib21","first-page":"S151","article-title":"Synaptic intervention in Alzheimer's disease: soluble A\u03b2 oligomer directed ACU193 monoclonal antibody therapeutic for treatment of early Alzheimer's disease","volume":"6","author":"Cline","year":"2019","journal-title":"J Prevent Alzheimer's Dis"},{"issue":"36","key":"10.14283\/jpad.2022.93_bib22","doi-asserted-by":"crossref","first-page":"11938","DOI":"10.1523\/JNEUROSCI.2357-10.2010","article-title":"Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines","volume":"30","author":"Zempel","year":"2010","journal-title":"J Neurosci"},{"issue":"1","key":"10.14283\/jpad.2022.93_bib23","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1038\/s41598-018-22979-2","article-title":"An acute functional screen identifies an effective antibody targeting amyloid-\u03b2 oligomers based on calcium imaging","volume":"8","author":"Wang","year":"2018","journal-title":"Scientific Reports"},{"issue":"4","key":"10.14283\/jpad.2022.93_bib24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/alzrt272","article-title":"Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics","volume":"6","author":"Goure","year":"2014","journal-title":"Alzheimers Res Ther"},{"issue":"8","key":"10.14283\/jpad.2022.93_bib25","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1523\/JNEUROSCI.1675-13.2014","article-title":"A sensitive A\u03b2 oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid","volume":"34","author":"Savage","year":"2014","journal-title":"J Neurosci"},{"key":"10.14283\/jpad.2022.93_bib26","unstructured":"Dodart J-C, Nay, S., Monbureau, M., Hefti, F. F., Jerecic, J., Shamloo, M. Passive immunization with the anti-A\u03b2 oligomer antibody ACU-3B3 improves behavioral deficits in hAPPSL transgenic mice. Presented at: Society for Neuroscience; 2014; Session 135.04\/G1."},{"issue":"7S","key":"10.14283\/jpad.2022.93_bib27","first-page":"595","article-title":"P2-063: Soluble A\u03b2-Oligomer-Selective Antibody ACU3B3 Reduces Amyloid Pathology & Improves Multiple Behavioral Domains in a Mouse Model of AD","volume":"15","author":"Ma","year":"2019","journal-title":"Alzheimer's and Dementia"},{"key":"10.14283\/jpad.2022.93_bib28","doi-asserted-by":"crossref","first-page":"862369","DOI":"10.3389\/fneur.2022.862369","article-title":"Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease","volume":"13","author":"Withington","year":"2022","journal-title":"Front Neurol"},{"issue":"4","key":"10.14283\/jpad.2022.93_bib29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer's disease","volume":"369","author":"Doody","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.14283\/jpad.2022.93_bib30","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.14283\/jpad.2022.93_bib31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.14283\/jpad.2022.93_bib32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol"},{"issue":"22","key":"10.14283\/jpad.2022.93_bib33","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1212\/WNL.0b013e31823a0ef7","article-title":"Voxel-level comparison of arterial spinlabeled perfusion MRI and FDG-PET in Alzheimer disease","volume":"77","author":"Chen","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.14283\/jpad.2022.93_bib34","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/mrm.25197","article-title":"Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: A consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia","volume":"73","author":"Alsop","year":"2015","journal-title":"Magn Reson Med"},{"issue":"5","key":"10.14283\/jpad.2022.93_bib35","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.drudis.2021.01.012","article-title":"Cognitive Go\/No-Go decision-making criteria in Alzheimer's disease drug development","volume":"26","author":"Wessels","year":"2021","journal-title":"Drug Discov Today"},{"issue":"4","key":"10.14283\/jpad.2022.93_bib36","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.14283\/jpad.2022.93_bib37","doi-asserted-by":"crossref","first-page":"211","DOI":"10.14283\/jpad.2022.21","article-title":"Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy","volume":"9","author":"Barakos","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"10.14283\/jpad.2022.93_bib38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/1567205010666131212110148","article-title":"A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease","volume":"11","author":"Grove","year":"2014","journal-title":"Curr Alzheimer Res"},{"key":"10.14283\/jpad.2022.93_bib39","unstructured":"Karin A. Validation of Cogstate cognitive test battery used in a clinical study with Alzheimer's disease patients. Master's Thesis. 2012."},{"issue":"2","key":"10.14283\/jpad.2022.93_bib40","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.trci.2015.06.003","article-title":"A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease","volume":"1","author":"Maher-Edwards","year":"2015","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"10.14283\/jpad.2022.93_bib41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13195-018-0431-6","article-title":"Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study","volume":"10","author":"Scheltens","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2022.93_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2021.02.003","article-title":"Lower cerebral perfusion is associated with tau-PET in the entorhinal cortex across the Alzheimer's continuum","author":"Rubinski","year":"2021","journal-title":"Neurobiology of Aging"},{"issue":"5","key":"10.14283\/jpad.2022.93_bib43","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2203395","article-title":"Trial of Cinpanemab in Early Parkinson's Disease","volume":"387","author":"Lang","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.14283\/jpad.2022.93_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trci.2016.01.001","article-title":"Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease","volume":"2","author":"Satlin","year":"2016","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724002450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724002450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T02:10:56Z","timestamp":1737339056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724002450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2274580724002450"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2022.93","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ACU193, a Monoclonal Antibody that Selectively Binds Soluble A\u03b2 Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2022.93","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}